ATE478143T1 - Hemmende oligonukleotide und deren verwendung zur spezifische hemmung von einem gen kodierend fur einen androgen-rezeptor - Google Patents

Hemmende oligonukleotide und deren verwendung zur spezifische hemmung von einem gen kodierend fur einen androgen-rezeptor

Info

Publication number: ATE478143T1
Authority: AT; Austria
Prior art keywords: pml; androgen receptor; gene coding; specific inhibition; complementary
Prior art date: 2001-11-09

Application number

AT02793219T

Other languages

English (en)

Inventor

Annick Harel-Bellan

Slimane Ait-Si-Ali

Florence Cabon-Georget

Anne Chauchereau

Francois Dautry

Luis Martinez

Original Assignee

Centre Nat Rech Scient

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-09

Filing date

2002-11-08

Publication date

2010-09-15

2002-11-08 Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient

2010-09-15 Application granted granted Critical

2010-09-15 Publication of ATE478143T1 publication Critical patent/ATE478143T1/de

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
230000005764 inhibitory process Effects 0.000 title abstract 2
108090000623 proteins and genes Proteins 0.000 title abstract 2
102000001307 androgen receptors Human genes 0.000 title 1
108010080146 androgen receptors Proteins 0.000 title 1
230000002401 inhibitory effect Effects 0.000 title 1
102100023606 Retinoic acid receptor alpha Human genes 0.000 abstract 2
230000000295 complement effect Effects 0.000 abstract 2
230000004927 fusion Effects 0.000 abstract 2
230000014509 gene expression Effects 0.000 abstract 2
108091008726 retinoic acid receptors α Proteins 0.000 abstract 2
108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 abstract 1
108020004414 DNA Proteins 0.000 abstract 1
108091028664 Ribonucleotide Proteins 0.000 abstract 1
238000004458 analytical method Methods 0.000 abstract 1
230000002456 anti-arthritic effect Effects 0.000 abstract 1
230000003178 anti-diabetic effect Effects 0.000 abstract 1
230000036436 anti-hiv Effects 0.000 abstract 1
230000002682 anti-psoriatic effect Effects 0.000 abstract 1
230000003356 anti-rheumatic effect Effects 0.000 abstract 1
230000000692 anti-sense effect Effects 0.000 abstract 1
239000003472 antidiabetic agent Substances 0.000 abstract 1
239000003435 antirheumatic agent Substances 0.000 abstract 1
239000000824 cytostatic agent Substances 0.000 abstract 1
230000001085 cytostatic effect Effects 0.000 abstract 1
239000005547 deoxyribonucleotide Substances 0.000 abstract 1
125000002637 deoxyribonucleotide group Chemical group 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
108020001507 fusion proteins Proteins 0.000 abstract 1
102000037865 fusion proteins Human genes 0.000 abstract 1
230000010534 mechanism of action Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
239000002336 ribonucleotide Substances 0.000 abstract 1
125000002652 ribonucleotide group Chemical group 0.000 abstract 1
239000012873 virucide Substances 0.000 abstract 1
238000001262 western blot Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Oncology (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Cardiology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Microbiology (AREA)
Communicable Diseases (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)

AT02793219T 2001-11-09 2002-11-08 Hemmende oligonukleotide und deren verwendung zur spezifische hemmung von einem gen kodierend fur einen androgen-rezeptor ATE478143T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
FR0114549A FR2832154B1 (fr)	2001-11-09	2001-11-09	Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene
FR0204474A FR2838442B1 (fr)	2001-11-09	2002-04-10	Sirnas inhibiteurs de l'expression de genes responsables de l'inactivation de la p53 et leur utilisation dans le traitement des cancers
PCT/FR2002/003843 WO2003040366A2 (fr)	2001-11-09	2002-11-08	Oligonucleotides inhibiteurs et leur utilisation pour reprimer specifiquement un gene

Publications (1)

Publication Number	Publication Date
ATE478143T1 true ATE478143T1 (de)	2010-09-15

Family

ID=26213261

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02793219T ATE478143T1 (de)	2001-11-09	2002-11-08	Hemmende oligonukleotide und deren verwendung zur spezifische hemmung von einem gen kodierend fur einen androgen-rezeptor

Country Status (12)

Country	Link
US (2)	US7371735B2 (de)
EP (3)	EP1453962B1 (de)
JP (1)	JP4323952B2 (de)
AT (1)	ATE478143T1 (de)
AU (1)	AU2002358881A1 (de)
CA (2)	CA2789407C (de)
CY (1)	CY1110915T1 (de)
DE (1)	DE60237391D1 (de)
DK (1)	DK1453962T3 (de)
FR (2)	FR2832154B1 (de)
PT (1)	PT1453962E (de)
WO (1)	WO2003040366A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0878552A1 (de)	1997-05-13	1998-11-18	Erasmus Universiteit Rotterdam	Molekularer Nachweis von chromosomalen Veränderungen
JP2002513587A (ja)	1998-05-04	2002-05-14	ダコエーエス	染色体異常を検出するための方法およびプローブ
DE19956568A1 (de)	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
DE10100586C1 (de) *	2001-01-09	2002-04-11	Ribopharma Ag	Verfahren zur Hemmung der Expression eines Ziegens
EP1438405A1 (de) *	2001-01-09	2004-07-21	Ribopharma AG	Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
WO2003035869A1 (de)	2001-10-26	2003-05-01	Ribopharma Ag	Verwendung einer doppelsträngigen ribonukleinsäure zur gezielten hemmung der expression eines vorgegebenen zielgens
US7423142B2 (en)	2001-01-09	2008-09-09	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of anti-apoptotic genes
US7745418B2 (en)	2001-10-12	2010-06-29	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting viral replication
DE10163098B4 (de)	2001-10-12	2005-06-02	Alnylam Europe Ag	Verfahren zur Hemmung der Replikation von Viren
EP1445312B1 (de) *	2001-11-21	2012-12-26	Astellas Pharma Inc.	Verfahren zur hemmung der genexpression
WO2004001045A1 (en) *	2002-06-20	2003-12-31	Dsm Ip Assets B.V.	Inhibition of nuclear receptors
US9719092B2 (en)	2002-11-14	2017-08-01	Thermo Fisher Scientific Inc.	RNAi targeting CNTD2
US10011836B2 (en)	2002-11-14	2018-07-03	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US9719094B2 (en)	2002-11-14	2017-08-01	Thermo Fisher Scientific Inc.	RNAi targeting SEC61G
US9879266B2 (en)	2002-11-14	2018-01-30	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
AU2003295600A1 (en)	2002-11-14	2004-06-15	Dharmacon, Inc.	Functional and hyperfunctional sirna
US7781575B2 (en) *	2002-11-14	2010-08-24	Dharmacon, Inc.	siRNA targeting tumor protein 53 (p53)
WO2006006948A2 (en)	2002-11-14	2006-01-19	Dharmacon, Inc.	METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US9228186B2 (en)	2002-11-14	2016-01-05	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US7612196B2 (en)	2002-11-14	2009-11-03	Dharmacon, Inc.	siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US9839649B2 (en)	2002-11-14	2017-12-12	Thermo Fisher Scientific Inc.	Methods and compositions for selecting siRNA of improved functionality
US9771586B2 (en)	2002-11-14	2017-09-26	Thermo Fisher Scientific Inc.	RNAi targeting ZNF205
US7144999B2 (en) *	2002-11-23	2006-12-05	Isis Pharmaceuticals, Inc.	Modulation of hypoxia-inducible factor 1 alpha expression
GB0306148D0 (en) *	2003-03-18	2003-04-23	Milner Jo	Regulation of gene expression
ES2423060T3 (es) *	2004-03-12	2013-09-17	Alnylam Pharmaceuticals, Inc.	Agentes iRNA que tienen como diana al VEGF
CN101277704A (zh)	2005-04-12	2008-10-01	因特拉迪格姆公司	用于治疗癌症及其它新血管生成疾病的RNAi治疗剂的组合物和方法
US7893244B2 (en)	2005-04-12	2011-02-22	Intradigm Corporation	Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
US20070082845A1 (en) *	2005-07-15	2007-04-12	The Penn State Research Foundation	Ferritin as a therapeutic target in abnormal cells
WO2007041497A2 (en) *	2005-09-30	2007-04-12	Cleveland Biolabs, Inc.	Modulation of androgen receptor
EP1844164B1 (de) *	2005-11-15	2010-07-14	Genoid KFT	Verfahren zum nachweis von pathogenen mittels molecular beacons
US7740880B2 (en) *	2006-03-03	2010-06-22	University Of Utah Research Foundation	Polymeric carrier for delivery of small interfering RNA
ES2911034T3 (es)	2006-08-08	2022-05-17	Univ Bonn Rheinische Friedrich Wilhelms	Estructura y uso de oligonucleótidos 5' fosfato
AR055648A1 (es) *	2006-09-21	2007-08-29	Gen Med Sa	Un oligonucleotido de rna de doble cadena una composicion farmaceutica o cosmetica que lo comprende y uso del mismo enla preparacion de un medicamento para el tratamiento de enfermedades relacionadas con el metabolismo de androgenos
WO2009031671A1 (ja) *	2007-09-07	2009-03-12	The University Of Tokushima	ｐ５３の発現促進方法およびそれに用いるｐ５３発現促進剤
DE102008014318B4 (de) *	2008-03-14	2021-02-04	Premark Feg L.L.C.	Transportspülmaschine und Verfahren zum Betreiben einer Transportspülmaschine
WO2009141146A1 (en)	2008-05-21	2009-11-26	Gunther Hartmann	5' triphosphate oligonucleotide with blunt end and uses thereof
WO2011005363A2 (en) *	2009-05-18	2011-01-13	Ensysce Biosciences, Inc.	Carbon nanotubes complexed with multiple bioactive agents and methods related thereto
MX2013000986A (es)	2010-07-28	2013-07-03	Alcon Res Ltd	Sirna dirigido al vegfa y metodos de tratamiento in vivo.
WO2012016139A2 (en)	2010-07-29	2012-02-02	Sirnaomics, Inc.	Sirna compositions and methods for treatment of hpv and other infections
EP2508530A1 (de)	2011-03-28	2012-10-10	Rheinische Friedrich-Wilhelms-Universität Bonn	Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
JP6112569B2 (ja)	2011-12-16	2017-04-12	国立大学法人東京医科歯科大学	キメラ２重鎖核酸
EP2867368B1 (de)	2012-07-06	2022-01-12	Institut Gustave Roussy	Gleichzeitiger nachweis von kannibalismus und seneszenz als prognostische marker für krebs
WO2014011512A1 (en)	2012-07-08	2014-01-16	Sirnaomics, Inc.	Compositions and methods for "resistance-proof" sirna therapeutics for influenza
EP2712870A1 (de)	2012-09-27	2014-04-02	Rheinische Friedrich-Wilhelms-Universität Bonn	Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
AR092982A1 (es)	2012-10-11	2015-05-13	Isis Pharmaceuticals Inc	Modulacion de la expresion de receptores androgenicos
MA40782A (fr) *	2014-10-03	2017-08-08	Hocuslocus Llc	Procédés et compositions utilisant un arn non codant en vue de la culture et de la sélection de cellules
WO2018078303A1 (fr) *	2016-10-27	2018-05-03	Selexel	Nouvel oligonucleotide double brin bisquecifiques pour le traitement des cancers
EP3755802A4 (de) *	2018-02-21	2021-11-17	Singapore Health Services Pte Ltd	Targeting von krebstherapeutika mittels mutierter p53-spezifischer sirna
EP3946629A4 (de) *	2019-03-26	2023-04-05	University Of Massachusetts	Therapeutische ziele für onkogene und s-abhängige krebs

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4714613A (en) *	1982-09-30	1987-12-22	The Albert Einstein College Of Medicine Of Yeshiva University	Method of suppressing cell growth by immunotherapy
US5165923A (en) *	1989-11-20	1992-11-24	Imperial Cancer Research Technology	Methods and compositions for the treatment of hodgkin's disease
AU692148B2 (en) *	1993-02-19	1998-06-04	Genta Incorporated	Treatment of androgen-associated baldness using antisense oligomers
US5641756A (en) *	1993-07-27	1997-06-24	Hybridon, Inc.	Modified VEGF oligonucleotides
WO1995011301A1 (en)	1993-10-19	1995-04-27	The Regents Of The University Of Michigan	P53-mediated apoptosis
US5556956A (en) *	1993-11-04	1996-09-17	Board Of Regents, The University Of Texas System	Methods and compositions relating to the androgen receptor gene and uses thereof
US5840301A (en) *	1994-02-10	1998-11-24	Imclone Systems Incorporated	Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US6150092A (en) *	1994-06-27	2000-11-21	Taogosei Company, Ltd.	Antisense nucleic acid compound targeted to VEGF
AU4961996A (en) *	1994-12-14	1996-07-03	Innovir Laboratories, Inc.	Ribozyme-mediated inactivation of leukemia-associated rna
US5882914A (en)	1995-06-06	1999-03-16	The Johns Hopkins University School Of Medicine	Nucleic acids encoding the hypoxia inducible factor-1
WO2002096927A2 (en) *	2001-05-29	2002-12-05	Ribozyme Pharmaceuticals, Incorporated	Ribozyme based treatment of female reproductive diseases
US6426335B1 (en) *	1997-10-17	2002-07-30	Gilead Sciences, Inc.	Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
WO2001052904A2 (en)	2000-01-19	2001-07-26	Gill Parkash S	Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides
SG117417A1 (en) *	1998-02-06	2005-12-29	Collateral Therpeutics Inc	Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
EP0978561A1 (de)	1998-08-07	2000-02-09	Hoechst Marion Roussel Deutschland GmbH	Antisense Oligonukleotide zur Hemmung von VEGF-Expression
US6214986B1 (en) *	1998-10-07	2001-04-10	Isis Pharmaceuticals, Inc.	Antisense modulation of bcl-x expression
AU771579B2 (en)	1998-10-26	2004-03-25	Avi Biopharma, Inc.	p53 antisense agent and method
KR20070118315A (ko) *	1999-04-21	2007-12-14	와이어쓰	폴리뉴클레오티드 서열의 기능을 억제하기 위한 조성물
GB9910119D0 (en)	1999-04-30	1999-06-30	Novartis Ag	Organic compounds
WO2000076497A1 (en)	1999-06-14	2000-12-21	Cancer Research Ventures Limited	Cancer therapy
GB9927444D0 (en) *	1999-11-19	2000-01-19	Cancer Res Campaign Tech	Inhibiting gene expression
DE10100586C1 (de) *	2001-01-09	2002-04-11	Ribopharma Ag	Verfahren zur Hemmung der Expression eines Ziegens
ES2336887T5 (es) *	2000-03-30	2019-03-06	Whitehead Inst Biomedical Res	Mediadores de interferencia por ARN específicos de secuencias de ARN
WO2003070910A2 (en) *	2002-02-20	2003-08-28	Ribozyme Pharmaceuticals, Incorporated	INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050148530A1 (en) *	2002-02-20	2005-07-07	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
JP2004535813A (ja)	2001-07-17	2004-12-02	ミルナー，アン，ジョセフィーヌ	遺伝子発現のサイレンシング
AU2003213119A1 (en) *	2002-02-20	2003-09-09	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF BCL2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7148342B2 (en) *	2002-07-24	2006-12-12	The Trustees Of The University Of Pennyslvania	Compositions and methods for sirna inhibition of angiogenesis
JP2005537015A (ja)	2002-09-04	2005-12-08	ジョンソンアンドジョンソンリサーチプロプライアトリーリミテッド	ＲＮＡ干渉（ＲＮＡｉ）を媒介するためにｄｓＤＮＡを使用する方法
NZ540779A (en)	2002-11-01	2008-05-30	Univ Pennsylvania	Compositions and methods for siRNA inhibition of HIF-1 alpha
ES2423060T3 (es) *	2004-03-12	2013-09-17	Alnylam Pharmaceuticals, Inc.	Agentes iRNA que tienen como diana al VEGF
KR101397407B1 (ko)	2008-03-05	2014-06-19	알닐람 파마슈티칼스 인코포레이티드	Ｅｇ5 및 ＶＥＧＦ 유전자의 발현을 억제하기 위한 조성물 및 방법
AU2010223967B2 (en) *	2009-03-12	2015-07-30	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
WO2011017548A1 (en)	2009-08-05	2011-02-10	Alnylam Pharmaceuticals, Inc.	Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
CN107519133A (zh)	2009-09-15	2017-12-29	阿尔尼拉姆医药品有限公司	脂质配制的组合物及抑制Eg5和VEGF基因的表达的方法

2001
- 2001-11-09 FR FR0114549A patent/FR2832154B1/fr not_active Expired - Lifetime
2002
- 2002-04-10 FR FR0204474A patent/FR2838442B1/fr not_active Expired - Fee Related
- 2002-11-08 CA CA2789407A patent/CA2789407C/fr not_active Expired - Lifetime
- 2002-11-08 US US10/494,800 patent/US7371735B2/en not_active Expired - Lifetime
- 2002-11-08 EP EP02793219A patent/EP1453962B1/de not_active Expired - Lifetime
- 2002-11-08 CA CA2466773A patent/CA2466773C/fr not_active Expired - Lifetime
- 2002-11-08 WO PCT/FR2002/003843 patent/WO2003040366A2/fr not_active Ceased
- 2002-11-08 EP EP16153703.0A patent/EP3037537A1/de not_active Withdrawn
- 2002-11-08 DE DE60237391T patent/DE60237391D1/de not_active Expired - Lifetime
- 2002-11-08 DK DK02793219.3T patent/DK1453962T3/da active
- 2002-11-08 EP EP08001984.7A patent/EP1939291B1/de not_active Expired - Lifetime
- 2002-11-08 AU AU2002358881A patent/AU2002358881A1/en not_active Abandoned
- 2002-11-08 JP JP2003542613A patent/JP4323952B2/ja not_active Expired - Fee Related
- 2002-11-08 PT PT02793219T patent/PT1453962E/pt unknown
- 2002-11-08 AT AT02793219T patent/ATE478143T1/de active
2008
- 2008-02-28 US US12/072,803 patent/US8318689B2/en not_active Expired - Fee Related
2010
- 2010-11-17 CY CY20101101030T patent/CY1110915T1/el unknown

Also Published As

Publication number	Publication date
AU2002358881A1 (en)	2003-05-19
CA2789407C (fr)	2017-10-31
WO2003040366A3 (fr)	2004-07-01
EP1453962B1 (de)	2010-08-18
EP1939291A3 (de)	2012-02-22
EP1939291A2 (de)	2008-07-02
FR2838442A1 (fr)	2003-10-17
FR2838442B1 (fr)	2007-06-08
CA2466773C (fr)	2012-10-16
CY1110915T1 (el)	2015-06-10
EP3037537A1 (de)	2016-06-29
DE60237391D1 (de)	2010-09-30
JP4323952B2 (ja)	2009-09-02
US20080287385A1 (en)	2008-11-20
DK1453962T3 (da)	2010-12-20
CA2466773A1 (fr)	2003-05-15
FR2832154A1 (fr)	2003-05-16
FR2832154B1 (fr)	2007-03-16
EP1939291B1 (de)	2016-08-17
WO2003040366A2 (fr)	2003-05-15
CA2789407A1 (fr)	2003-05-15
EP1453962A2 (de)	2004-09-08
US20050215497A1 (en)	2005-09-29
JP2005508188A (ja)	2005-03-31
US7371735B2 (en)	2008-05-13
US8318689B2 (en)	2012-11-27
PT1453962E (pt)	2010-11-29

Legal Events

Date

Code

Title

Description

2011-03-15

UEP

Publication of translation of european patent specification

Ref document number: 1453962

Country of ref document: EP

Publication	Publication Date	Title
ATE478143T1 (de)	2010-09-15	Hemmende oligonukleotide und deren verwendung zur spezifische hemmung von einem gen kodierend fur einen androgen-rezeptor
Watson et al.	1987	Primate brain-specific cytoplasmic transcript of the Alu repeat family
EP2363479B1 (de)	2016-07-13	Oligoribonukleotid zur Hemmung der Expression eines vorgegebenen Gens
Schmid et al.	1982	The Alu family of dispersed repetitive sequences
Arzumanov et al.	2001	Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2 ‘-O-methyl/LNA oligoribonucleotides
Faria et al.	2001	Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo
Morgan et al.	1983	Rho-dependent termination of transcription. II. Kinetics of mRNA elongation during transcription from the bacteriophage lambda PR promoter.
Toscano-Garibay et al.	2014	Transcriptional regulation mechanism mediated by miRNA–DNA• DNA triplex structure stabilized by Argonaute
ATE189264T1 (de)	2000-02-15	Chimärisches oligonukleotid und dessen verwendung zur herstellung von nukleinsäure-transkripten
JP2017537626A5 (de)	2019-01-17
IL166546A (en)	2014-01-30	Double-stranded ribonucleic acid, preparations containing it, is used in drug preparation and in vitro method to inhibit the expression of a target gene
CA2173361A1 (en)	1995-04-20	Antisense oligonucleotide generators
ZA200304500B (en)	2003-11-18	Method for inhibiting the expression of a target gene and medicament for treating a tumor disease.
IL185569A0 (en)	2008-01-06	Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
ATE478687T1 (de)	2010-09-15	Zur mutation geeignete einzelsträngige oligonukleotid vektoren
WO2019005851A1 (en)	2019-01-03	UNIVERSAL PLATFORM FOR ENHANCED CRISPR GENE EDITION FOR IN VIVO THERAPIES
Tanaka et al.	1994	Sequence-specific interaction of α β-anomeric doublestranded DNA with the p50 subunit of NFxB: application to the decoy approach
Williamson	1993	G-quartets in biology: reprise.
DE19520815A1 (de)	1995-12-21	Replikatives und transkriptionsaktives Peptid-Nukleinsäureplasmid, sowie seine Verwendung zur Einbringung in Zellen und Zellorganellen
EP3040423A3 (de)	2016-10-26	Mikro-rna und verwendung davon
EP3583215B1 (de)	2025-03-19	System und verfahren zur zelltyp-spezifischen translation von rna-molekülen in eukaryoten
WO2004015117A3 (en)	2004-06-03	Targeted gene modification by single-stranded dna oligonucleotides
Okada et al.	1985	Many highly repetitive and transcribable sequences are derived from tRNA genes
Xu et al.	2019	Gene activation by a CRISPR-assistant trans enhancer
AU2001258274A1 (en)	2001-09-24	Synthetic oligonucleotides as inducers of erythroid differentiation